Howard Kallender

5PUBLICATIONS
23CO-AUTHORS
Adolescent healthInfant and child healthMolecular medicineCancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 27, 2026
Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.

|Jan 06, 2025
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis.

Linda Stein Gold, Robert Bissonnette, Seth Forman

|Oct 07, 2024
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.

Andrew Blauvelt, Howard Kallender, Daniel Sturm

|Jul 12, 2024
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.

Eric L Simpson, Leon Kircik, Andrew Blauvelt

|Apr 08, 2020
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.

Jason D Lickliter, Hui K Gan, Mark Voskoboynik

Pageof 1

Frequent Collaborators

2 joint publications

Lawrence F Eichenfield

2 joint publications

Andrew Blauvelt

2 joint publications

Daniel Sturm

1 joint publications

Mark Voskoboynik